Uncovering Discovery & Translation of Next Generation TCR-Based Bispecifics Against Novel Intracellular Cancer Targets
- Novel approach to T-cell engagers against intracellular targets: T-Cypher uses TCR-based bispecifics to target intracellular cancer antigens that conventional therapies can’t reach
- Proprietary AI discovery platform: An internally-developed engine rapidly identifies and optimises high-affinity TCRs with exceptional safety profiles
- Two lead programs moving toward the clinic: Advanced pipeline with near-term IND filings and clear clinical development timelines